Omeros Strategy and Business Model

Executive Overview

Omeros is a Seattle-based clinical-stage biopharmaceutical company founded in 1994 and focused on complement-mediated, inflammatory, and rare diseases. The company is best known historically for Omidria, an ophthalmic drug approved in 2014, but its current strategy is centered on a narrow set of high-value biologic programs rather than a broad marketed portfolio. Its lead asset, narsoplimab, inhibits mannan-binding lectin-associated serine protease-2 (MASP-2) and has been developed for transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. A second major program, OMS906, targets MASP-3 for paroxysmal nocturnal hemoglobinuria and other alternative-pathway disorders. That places Omeros in the rare-disease biotechnology and complement-therapeutics space, where value depends more on clinical differentiation, regulatory execution, and capital discipline than on current scale. Omeros’s physical footprint is U.S.-centered, with headquarters in Seattle and a broader international reach through clinical trials, patents, and potential future partnerships. As of FY2023, revenue remained modest, underscoring that Omeros is best understood primarily as a development-stage biotech whose economics hinge on pipeline progress rather than current product sales.

Omeros at a Glance

Logo
Common name	Omeros
Full legal name	Omeros Corporation
Headquarters	Seattle, Washington, United States
Ownership	Public company; Nasdaq-listed; no controlling shareholder publicly disclosed as of 2024
Ticker	OMER
Exchange	NASDAQ
Market Cap	$758.86M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1994; initial public offering in 2009; Omidria approved by the U.S. Food and Drug Administration in 2014; Omidria sold to Rayner in 2021; strategic focus shifted to complement pipeline led by narsoplimab and OMS906
Industry or industries	Biotechnology; biopharmaceuticals; rare-disease therapeutics; complement biology
Key products or services	Narsoplimab; OMS906; earlier-stage complement and G protein-coupled receptor programs; historical Omidria asset divested in 2021
Geographic footprint	U.S.-centered operations with broader multinational clinical-development activity
Business segments as officially reported	One reportable segment: biopharmaceuticals
Company website	https://www.omeros.com

1. What Is the Strategy of Omeros?

1a. What is the winning aspiration of Omeros?

Omeros’s public positioning through 2023 and early 2024 points to a clear aspiration: build value by developing and, where appropriate, commercializing differentiated therapeutics for severe diseases with high unmet need, especially where complement biology offers a targeted mechanism and specialist-market economics. In practice, “winning” for Omeros does not mean becoming a broad primary-care drug company. It means securing meaningful clinical and regulatory success in a small number of serious indications, then translating that into orphan or specialty-biopharma economics.

The company has not centered its public narrative on a large corporate revenue target. Instead, the more concrete markers of success have been clinical progress, regulatory advancement, and eventual approval of lead assets such as narsoplimab and OMS906.
1b. Where does Omeros play?

Omeros plays in a narrow part of the biotechnology market: rare and serious diseases where the complement system, inflammatory pathways, or related immunologic mechanisms are central. Its most visible focus areas as of 2024 were transplant-associated thrombotic microangiopathy, immunoglobulin A nephropathy, and paroxysmal nocturnal hemoglobinuria. Those are specialist-driven markets served by transplant centers, nephrologists, hematologists, and hospital systems rather than mass-prescribing physicians.

Geographically, Omeros is U.S.-centered operationally, but its development ambitions are broader because rare-disease biologics often need multinational trial sites, international patent coverage, and potential ex-U.S. commercial partners.
1c. How does Omeros plan to win?

Omeros’s apparent plan to win is to pursue differentiated biology at targeted nodes of the complement cascade rather than compete solely through commercial scale. Narsoplimab targets MASP-2 in the lectin pathway, while OMS906 targets MASP-3 in the alternative pathway. Management’s strategic case has been that these pathway-specific approaches could produce strong efficacy in selected diseases while offering a differentiated mechanism versus broader complement inhibition.

The company also appears to be choosing indications where patient populations are concentrated, clinical need is acute, and a successful drug could command specialty pricing. That is a classic rare-disease strategy: narrow market, high medical need, focused sales effort, and deep account-level engagement rather than wide commercial reach.
1d. What capabilities must Omeros have in place?

To execute this strategy, Omeros needs strong capabilities in complement biology, monoclonal-antibody development, rare-disease clinical-trial design, regulatory strategy, chemistry, manufacturing, and controls for biologics, and intellectual-property management. Because the company is relatively small, it also needs to be good at running an outsourced development model through contract research and manufacturing partners without losing scientific or quality control.

Just as important, Omeros needs disciplined portfolio management. A company with a concentrated pipeline cannot afford to spread capital too thinly across too many programs.
1e. What management systems does Omeros require?

Omeros needs management systems built around capital allocation, development governance, and regulatory rigor. In practical terms, that means tight program-level decision making, milestone-based spending, formal quality systems for biologics manufacturing and clinical operations, and careful coordination among R&D, regulatory, medical, legal, and finance teams.

Because Omeros is a development-stage public company, investor communication and cash-runway management are also strategic management systems, not just finance tasks. The company needs to continually balance scientific ambition with the realities of trial timing, evidence thresholds, and capital availability.

2. What Are the Current Strategic Initiatives of Omeros?

Based on company disclosures in 2023 and early 2024, Omeros’s current strategic initiatives were concentrated around a small number of clinical and corporate priorities.

Advance narsoplimab toward a regulatory path in transplant-associated thrombotic microangiopathy.
Omeros continued working to define a path forward for narsoplimab in transplant-associated thrombotic microangiopathy following the earlier U.S. Food and Drug Administration complete response letter. This initiative is strategically important because it could create the company’s first major rare-disease launch opportunity in a setting with high unmet need and concentrated specialist accounts.
Run the Phase 3 ARTEMIS-IGAN program for immunoglobulin A nephropathy.
The company has been pursuing a later-stage development program for narsoplimab in immunoglobulin A nephropathy. This matters because IgA nephropathy is a larger market than ultra-rare transplant complications, but it is also more competitive and more demanding in terms of clinical evidence and payer scrutiny.
Generate clinical proof points for OMS906 in paroxysmal nocturnal hemoglobinuria and related complement disorders.
OMS906 is strategically important because it gives Omeros a second major shot on goal in complement therapeutics. Public updates through 2023 and 2024 emphasized building the clinical dataset and clarifying where OMS906 may be differentiated.
Concentrate resources on the complement franchise.
Omeros has long had broader scientific interests, including G protein-coupled receptor programs, but the center of gravity has been its complement portfolio. That concentration reflects financial discipline as much as scientific conviction.
Preserve financing flexibility.
As a company with limited current revenue, Omeros’s strategy necessarily includes runway management, prioritization of high-value programs, and potential use of partnerships, asset monetization, or capital-markets activity to fund development.
Prepare for potential specialty commercialization without overbuilding overhead too early.
Omeros appears to be maintaining optionality for launch in concentrated specialist markets while avoiding the fixed cost structure of a large commercial organization before regulatory visibility improves.

3. What Is the Business Model of Omeros?

Omeros’s business model is best understood as a development-stage specialty-biopharma model, not a scaled commercial pharma model. Today, the company’s economic value is driven primarily by pipeline assets, intellectual property, and potential future approvals rather than by a broad base of product revenue.

What customers actually buy

If Omeros succeeds commercially, customers will ultimately buy high-value specialty biologics for severe diseases treated by specialists and hospital centers. In the near term, however, Omeros is still largely building future products rather than broadly selling current ones.

Recurring or repeat-driven versus one-time revenue

The eventual commercial model could include recurring treatment revenue in chronic or relapsing diseases such as immunoglobulin A nephropathy or paroxysmal nocturnal hemoglobinuria. Some hospital-based uses could be more episodic, but still repeat-driven across a patient population. By contrast, current inflows are more likely to be irregular, including residual legacy revenue, milestone-related items, or financing events rather than predictable recurring product sales.

How pricing power works

In rare-disease biopharma, pricing power comes less from volume and more from clinical value, unmet need, and lack of alternatives. If Omeros can show meaningful efficacy and acceptable safety in serious diseases, it could support specialty pricing. But pricing power would still be constrained by payer evidence requirements, competitive products, and formulary access.

Why the business mix matters

Omeros has moved away from being partly supported by a commercial ophthalmology asset and toward a more concentrated pipeline model. That changes the risk profile. It increases upside if a lead program succeeds, but it also makes results more sensitive to clinical, regulatory, and financing events.

What drives gross margin, operating margin, and cash generation

For approved biologics, gross margin can be attractive because pricing in rare disease is often high relative to unit manufacturing cost. At Omeros today, however, operating margin is dominated by research and development expense, clinical operations, manufacturing readiness, and public-company overhead. Cash generation is therefore negative and depends heavily on capital discipline until commercial revenue arrives.

Revenue model

The likely long-term revenue model is a mix of direct specialty-drug sales in selected markets, potential ex-U.S. partnerships, and possibly milestones or royalties tied to collaborations or legacy assets. As of 2024, Omeros remained primarily a pipeline company rather than a mature seller of medicines.

4. What Products and/or Services Does Omeros Sell?

As of 2024, Omeros’s most important offerings were investigational therapeutics rather than a broad portfolio of approved commercial products.

Narsoplimab.
Narsoplimab is Omeros’s lead clinical asset and a monoclonal antibody targeting MASP-2 in the lectin pathway of complement. Strategically, it is the company’s most important program because it has been pursued in both transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy.
OMS906.
OMS906 targets MASP-3 in the alternative pathway and is a key second program for the company. It matters because it broadens Omeros’s relevance in complement therapeutics and gives it another potential route to commercial value creation beyond narsoplimab.
Earlier-stage complement and receptor-based programs.
Omeros has historically maintained additional discovery and preclinical assets, including programs linked to complement biology and G protein-coupled receptors. These contribute option value, but they appear less central than the lead complement assets.
Legacy product: Omidria.
Omidria, used in cataract and lens-replacement surgery, was historically Omeros’s marketed product and an important proof point that the company could get a drug approved and reimbursed. Omeros sold Omidria to Rayner in 2021, so it is no longer the company’s core operating product.

In short, Omeros is no longer a story about a marketed ophthalmology drug. It is a story about whether one or more complement-focused development assets can become commercially meaningful specialty medicines.

5. What Are the Key Competitors or Peers of Omeros?

Omeros does not face one single competitor across all of its activities. Competition is indication-specific and mechanism-specific. As of mid-2024, the most relevant competitors and peers included the following:

AstraZeneca / Alexion.
The benchmark competitor in complement-mediated rare disease, with Soliris and Ultomiris in paroxysmal nocturnal hemoglobinuria and other complement disorders. This is the most established direct comparator for any company trying to build a complement franchise.
Apellis Pharmaceuticals.
A direct competitor in complement therapeutics, particularly in paroxysmal nocturnal hemoglobinuria through Empaveli. Apellis matters because it shows that differentiated complement mechanisms can carve out meaningful positions even in markets with entrenched incumbents.
Roche.
Roche is relevant through crovalimab in paroxysmal nocturnal hemoglobinuria and its broader immunology capabilities. It is a direct competitor by indication in PNH and a scale competitor by resources.
Novartis.
Novartis is relevant both in complement therapeutics and in nephrology. It has major scale, kidney-disease ambitions, and a growing role in rare immunologic disorders, making it an important competitor or partner-type comparator depending on indication.
Travere Therapeutics.
Travere is a direct indication competitor in immunoglobulin A nephropathy through Filspari. For Omeros, Travere represents the kind of kidney-focused specialty-commercial model needed if narsoplimab succeeds in IgAN.
Calliditas Therapeutics.
As of mid-2024, Calliditas was an important IgA nephropathy competitor through Tarpeyo. It is less a mechanism match than an indication-level competitor for nephrologists, payers, and treatment sequencing.
Vera Therapeutics.
Vera is a relevant late-stage peer in IgA nephropathy and a good example of how kidney-disease competition increasingly comes from focused biotech players rather than only large pharma.
Annexon Biosciences.
Annexon is more a pathway and business-model peer than a direct indication competitor. It is relevant because it reflects investor and industry interest in complement-targeted rare-disease development.

For Omeros, the most practical competitive battlegrounds are transplant medicine, nephrology, and complement-mediated hematology. In those markets, scientific differentiation alone is not enough; regulatory timing, payer evidence, and launch execution also matter.

6. What Is the Marketing Strategy of Omeros?

Omeros’s current marketing strategy appears to be science-led and pre-commercial. Because the company does not currently operate a large marketed-drug portfolio, marketing is not built around mass physician promotion, consumer advertising, or broad brand campaigns. Instead, it is centered on market development in specialist communities.

Medical and scientific communication. Conference presentations, publications, and disease-state education are more important than traditional brand advertising.
Key opinion leader engagement. In rare disease and specialty nephrology or hematology, a relatively small number of expert physicians and transplant centers can heavily influence adoption.
Reimbursement and access preparation. For high-cost biologics, payer evidence and economic justification matter early, especially in hospital or specialist settings.
Targeted launch planning. If approved, Omeros would likely need a narrow, high-touch commercial model focused on centers of excellence rather than a broad sales footprint.

Historically, Omidria required targeted ophthalmology and reimbursement-oriented promotion. Post-divestiture, Omeros’s marketing burden is different: less commercial promotion today, more scientific credibility and future launch readiness. Based on public disclosures, marketing is a supporting capability, not the primary source of differentiation; clinical data and regulatory progress are.

7. What Are the Key Customer Segments of Omeros?

Because Omeros is still primarily a development-stage company, its most important customer segments are better understood as future prescribing, reimbursement, and partnering stakeholders rather than a large base of current product buyers.

Transplant centers and hospital specialists.
These are central for transplant-associated thrombotic microangiopathy. If narsoplimab advances, a relatively small number of sophisticated centers could account for a large share of use.
Nephrologists and kidney specialty practices.
These matter for immunoglobulin A nephropathy. This segment is larger than ultra-rare transplant medicine but still specialized and evidence-driven.
Hematologists treating complement-mediated disorders.
This is the key segment for OMS906 in paroxysmal nocturnal hemoglobinuria and related disorders.
Hospital pharmacies, integrated delivery systems, and specialty distributors.
These stakeholders matter because access, formulary decisions, and drug handling are critical in specialty biologics.
Payers.
Commercial insurers, Medicare-related channels, and other reimbursement bodies are essential economic customers because they determine access conditions for expensive rare-disease therapies.
Potential ex-U.S. partners.
For a small biotech, regional commercial partners can also function as important customers or counterparties in a licensing sense.

Omeros is therefore not diversified across many end markets. Its future commercial exposure would likely be concentrated in a handful of specialist disease areas and concentrated prescribing centers.

8. What Is the Sales Model of Omeros?

As of 2024, Omeros did not operate a large-scale commercial sales model. Its likely future model, if key assets are approved, would be a targeted specialty-sales approach.

How products would reach end customers

For rare-disease biologics, the typical route is a small direct field team supported by medical science liaisons, reimbursement specialists, specialty pharmacy or specialty distributor relationships, and hospital-account management. That is the model Omeros would most plausibly use in the United States.

Direct versus partner channels

In the U.S., a direct commercial presence would make sense for concentrated specialist markets such as transplant centers, nephrology, and hematology. Outside the U.S., partnering would often be more economical for a company of Omeros’s size. That is an inference from the structure of similar biotech launches rather than a company commitment.

How channel structure affects growth and pricing

The advantage of a concentrated channel is focus: a small number of accounts can be covered deeply. The drawback is concentration risk. A limited set of payer and center decisions can have an outsized effect on launch trajectory, pricing realization, and adoption speed.

Consultant relevance

Because the likely sales model is narrow and specialist-heavy, external consultants can be especially useful in launch planning, account segmentation, market-access design, and operating-model buildout before a full commercial team is hired.

9. In What Geographies Does Omeros Operate?

Omeros’s physical footprint is concentrated in the United States, with headquarters in Seattle, Washington. The company’s corporate, research oversight, and development leadership are primarily U.S.-based.

Its strategic footprint is broader than its office footprint, however. Like many biotech companies, Omeros extends internationally through:

multinational clinical-trial sites,
international patent filings and intellectual-property strategy,
potential regulatory ambitions beyond the United States, and
possible future commercialization or licensing relationships in major pharmaceutical markets.

Omeros does not resemble a global big-pharma company with a wide owned manufacturing and sales network. It is better described as U.S.-centered operationally and internationally relevant through development and partnering activity.

10. Who Are the Owners of Omeros?

Omeros is a publicly traded company listed on Nasdaq under the ticker OMER. As of 2024, it did not appear to have a controlling shareholder.

Ownership was broadly distributed among institutional investors and insiders. Public filings around 2024 showed large institutional holders that included major asset managers such as BlackRock and Vanguard, while founder and Chief Executive Officer Gregory A. Demopulos also held a meaningful insider stake. These holdings are time-sensitive and can change with each reporting period.

11. How Is Omeros Organized?

As officially reported, Omeros operates as one reportable segment: biopharmaceuticals. It is not organized as a multi-division conglomerate with separate consumer, generic, and branded units.

At a practical level, the company appears to be organized around a small number of core functions:

research and development,
clinical development and medical affairs,
regulatory and quality,
chemistry, manufacturing, and controls oversight,
intellectual property and legal, and
finance and public-company administration.

The business is also program-centered. Narsoplimab and OMS906 have been the most important organizing assets strategically, with other earlier-stage programs carrying lower near-term weight. Omeros relies on outside vendors for meaningful parts of clinical and manufacturing execution, so its effective operating structure extends beyond its employee base.

12. How Does Omeros Operate?

Omeros operates like a focused biotech developer. Day to day, value is created by turning scientific hypotheses about complement and related pathways into clinical data packages, regulatory interactions, and potentially approvable specialty medicines.

That operating model includes several core activities:

advancing drug candidates through preclinical and clinical development,
designing and managing trials in rare or specialist-treated diseases,
working with contract manufacturers on biologic production and quality control,
managing regulatory submissions and agency interactions,
protecting intellectual property, and
raising and allocating capital to the highest-priority programs.

The main operational complexities are typical of development-stage biotech but especially acute in rare disease: small patient pools, difficult site activation, endpoint selection, biologics manufacturing consistency, and the need to maintain credibility with regulators and investors even when timelines shift. For Omeros, operational excellence is less about factory throughput than about trial execution, evidence quality, and disciplined use of cash.

13. What Are the Growth Opportunities for Omeros?

Omeros’s growth opportunities are real, but they are highly concentrated and tied to a small number of development outcomes.

Narsoplimab approval and launch in transplant-associated thrombotic microangiopathy.
This is the most obvious upside opportunity because it could establish Omeros as a commercial rare-disease company in a concentrated specialist market.
Expansion in immunoglobulin A nephropathy.
Success in IgA nephropathy would open a larger nephrology market than the transplant setting, though one with more competition and a heavier evidence burden.
OMS906 development in paroxysmal nocturnal hemoglobinuria and related complement disorders.
If OMS906 shows clinically compelling differentiation, it could create a second major value driver and reduce Omeros’s dependence on a single asset.
Platform expansion across complement-mediated diseases.
Omeros’s broader opportunity is to reuse pathway knowledge across multiple indications rather than create a one-asset company.
Partnerships outside the United States or in selected indications.
Partnering could accelerate development, reduce funding pressure, or widen geographic reach without requiring Omeros to build full infrastructure alone.

The main constraints are equally clear: clinical and regulatory uncertainty, limited current revenue, the need for continuing capital, and growing competition in complement therapeutics and kidney disease. In other words, Omeros has meaningful upside if its lead programs work, but the path is narrow and execution-sensitive.

14. What Is the History of Omeros?

Omeros was founded in 1994 in Seattle by Gregory A. Demopulos. From the beginning, the company’s identity was that of a science-driven biotechnology business rather than a large diversified pharmaceutical operator.

1994: Omeros was founded in Seattle.
2009: The company completed its initial public offering and became a Nasdaq-listed biotech.
2014: Omidria received U.S. Food and Drug Administration approval, giving Omeros its first marketed product and proving it could move a drug through approval and commercialization.
2021: Omeros sold Omidria to Rayner, a major portfolio move that shifted the company more decisively toward a pipeline-focused model.
2021 onward: The company continued to pursue narsoplimab in transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy while advancing OMS906 in complement-mediated blood disorders.

The broad arc of Omeros’s history is a shift from mixed commercial-and-development biotech to a more concentrated complement-focused development-stage company.

15. How Does the Supply Chain of Omeros Function?

Omeros’s supply chain is important, but it does not look like the supply chain of a mass-market pharmaceutical company. It is a specialty biologics development supply chain built around external partners, quality control, and reliability rather than very high unit volume.

Manufacturing model. Omeros appears to rely heavily on third parties for biologic drug substance manufacturing, fill-finish, packaging, and release testing.
Clinical supply. Investigational drug must be produced to regulatory standards and distributed to trial sites with appropriate handling and documentation, often under controlled-temperature conditions.
Low-volume, high-consequence logistics. Rare-disease products may involve fewer doses than mass-market drugs, but stockouts, quality failures, or comparability issues can be disproportionately damaging.
Regulatory linkage. In biotech, supply-chain execution is tightly tied to regulatory success. Manufacturing consistency and documentation can be as important as physical delivery.

For Omeros, the supply-chain challenge is less about global scale and more about reducing single-source risk, maintaining biologics quality, and making sure clinical or eventual commercial supply does not become the bottleneck.

16. What Are the Key Assets of Omeros?

Omeros’s most important assets are primarily intangible and clinical, not physical plants or heavy infrastructure.

Narsoplimab.
This is the company’s most important asset because it anchors multiple indications and much of Omeros’s strategic value.
OMS906.
This is the key follow-on asset that could broaden Omeros’s role in complement therapeutics and reduce asset concentration risk.
Intellectual property.
Patent positions and know-how around complement-pathway targets and related programs are central to Omeros’s long-term defensibility.
Clinical and regulatory data packages.
In biotech, trial data, safety records, regulatory interactions, and manufacturing dossiers are assets in their own right.
Scientific team and disease expertise.
A focused biotech’s human capital in a specialized pathway area can be a major asset, particularly in rare disease.
Public-market access.
Omeros’s Nasdaq listing and ability to access capital are important strategic assets for a company still funding development.

Omeros is therefore not especially asset-heavy in the industrial sense. Its key assets are scientific programs, intellectual property, and capital-market access.

17. What Is the R&D Strategy of Omeros?

R&D is the core of Omeros’s strategy. The company’s research and development approach appears to have several defining features.

Mechanism-led focus.
Omeros has concentrated on defined biological targets within the complement system rather than pursuing a broad scattershot pipeline.
Orphan and specialty disease orientation.
The company has emphasized indications where unmet need is high, specialist care is concentrated, and a strong biologic could support premium economics.
Platform logic across indications.
Rather than treating each disease as a standalone effort, Omeros appears to be using pathway knowledge to extend assets into multiple diseases where the same biology may matter.
Capital-aware prioritization.
As a smaller biotech, Omeros cannot fund every scientific idea equally. Public disclosures suggest a practical concentration on lead complement assets over less near-term programs.
Hybrid internal-external execution.
Strategic science and asset leadership remain internal, while many development and manufacturing tasks are executed through outside partners.

The main R&D question for Omeros is not whether it has scientific ideas. It is whether it can sequence them well enough, fund them adequately, and generate data strong enough to overcome increasing competition in complement and kidney disease.

18. What Is the Finance Strategy of Omeros?

Omeros’s finance strategy is shaped by a simple reality: it is funding expensive clinical development without a large current revenue base. As a result, finance is not just back-office administration; it is central to strategy.

Preserve runway.
The company’s first finance priority is maintaining enough liquidity to advance the highest-value programs through meaningful milestones.
Prioritize capital allocation.
Omeros needs to decide which indications and assets deserve the next dollar of spend. For a concentrated biotech, portfolio discipline matters more than accounting optimization.
Keep overhead relatively lean.
A smaller biotech typically avoids building a full commercial organization too early. That appears consistent with Omeros’s posture after divesting Omidria.
Use strategic financing tools when needed.
Asset monetization, partnerships, equity issuance, debt, or structured financing can all be part of the toolkit. The Omidria divestiture in 2021 is an example of capital strategy supporting pipeline focus.
Align finance with development milestones.
The practical finance calendar is driven by data readouts, regulatory events, and manufacturing readiness more than by traditional seasonal sales cycles.

For Omeros, the critical finance metrics are cash runway, dilution risk, and the return on each development dollar. Until the company regains meaningful recurring revenue, capital efficiency remains one of management’s most important strategic tests.

19. How Companies Like Omeros Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. A company like Omeros can use Umbrex when it needs high-caliber strategy, operations, finance, technology, ERP, or AI support without hiring a full consulting team and carrying all of the associated overhead. For a focused biotech with a concentrated pipeline, that is often the right model: bring in deep expertise for a defined problem, move quickly, and keep fixed costs under control.

Portfolio prioritization and capital-allocation review across narsoplimab, OMS906, and earlier-stage programs.
Launch strategy design for a potential transplant-associated thrombotic microangiopathy product, including center-of-excellence targeting and account segmentation.
IgA nephropathy market assessment covering competitor positioning, treatment pathways, and implications for go-to-market sequencing.
Rare-disease pricing and market-access strategy for specialist and hospital-administered biologics.
Clinical-operations performance improvement to accelerate enrollment, strengthen site productivity, and improve trial-governance dashboards.
External manufacturing and CMC operating-model review to reduce supply risk and improve coordination with contract manufacturers.
Business-development support for ex-U.S. partnering, deal screening, and licensee prioritization.
Medical-affairs and key-opinion-leader mapping in transplant medicine, nephrology, and hematology.
Finance transformation and runway extension work, including zero-based budgeting, spend analytics, and scenario planning.
AI-enabled knowledge workflows for competitive intelligence, regulatory document support, and clinical-information management.